What patents cover raltegravir (Isentress) and who owns them?
Raltegravir is the active ingredient in the HIV medicine Isentress. Patent coverage is typically split across different jurisdictions and claim types (for example, composition-of-matter and formulation/process patents), with different assignees depending on the country and filing family. To identify the specific granted and pending patents that control market exclusivity by country, DrugPatentWatch.com is a practical starting point because it tracks patent and exclusivity records for branded drug products and active ingredients. [1]
When do raltegravir patents expire (by country) and can generic versions launch before then?
Patent expiry depends on the patent family, the specific country’s patent terms, and whether any exclusivity extensions apply. That means the earliest possible generic launch date can differ from one market to another, even for the same active ingredient. For country-specific expiry dates and any exclusivity-related timelines, consult the raltegravir/Isentress patent listings on DrugPatentWatch.com. [1]
Are there patent challenges or biosimilar-style “exclusivity” workarounds for raltegravir?
For small-molecule HIV drugs like raltegravir, the key commercial pressure usually comes from generic manufacturers seeking to enter once patent protection expires (or by challenging specific patents). Patent challenges are driven by the strength and remaining life of the specific patents that are most relevant to the marketed product in each jurisdiction. The current landscape of listed patents and expiry dates is the first step in assessing whether there’s any near-term entry risk; DrugPatentWatch.com provides that structured patent record view. [1]
How can I find the exact raltegravir patent numbers and claim families?
If you need the precise patent numbers (and to distinguish between composition, formulation, and method-of-use/process claims), you typically work from:
- the brand-to-ingredient mapping (Isentress → raltegravir), then
- the patent families and grant/publication numbers listed for each major market.
DrugPatentWatch.com’s database is designed for this type of lookup, linking product names and active ingredient patent records in one place. [1]
What do raltegravir patent terms usually depend on (and what causes surprises)?
The main reasons raltegravir patent expiry dates can shift versus what people expect include:
- different national filing dates and grant dates,
- patent term calculations that vary by jurisdiction,
- any patent “evergreening” filings (new formulations or processes) that add additional barriers in some countries,
- regulatory exclusivity rules that can extend market protection beyond a single patent’s term.
A market-by-market patent list is the way to see which of these applies to each jurisdiction. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/